DAWN
Day One Biopharmaceuticals Inc

1,800
Loading...
Loading...
News
all
press releases
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 303.5% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
News Placeholder
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
chainwire·5mo ago
News Placeholder
Futures Drop As Japan, European Stocks Tumble On AI Bubble Bursting Fears
Futures Drop As Japan, European Stocks Tumble On AI Bubble Bursting Fears US equity futures are lower but well off their worst levels, after a rout in Japan sent the Nikkei tumbling...
Zero Hedge·1y ago
News Placeholder
Piper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Day One Biopharmaceuticals (DAWN Research Report) today and set a price target...
TipRanks Financial Blog·1y ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Piper Sandler
Day One Biopharmaceuticals (NASDAQ:DAWN Get Free Report)s stock had its overweight rating reiterated by equities research analysts at Piper Sandler in a research report...
Zolmax·1y ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns "Overweight" Rating from Piper Sandler
Day One Biopharmaceuticals (NASDAQ:DAWN Get Free Report)s stock had its overweight rating reaffirmed by equities research analysts at Piper Sandler in a research note...
Ticker Report·1y ago
News Placeholder
Commit To Purchase Day One Biopharmaceuticals At $12.50, Earn 52.8% Annualized Using Options
Investors eyeing a purchase of Day One Biopharmaceuticals Inc (DAWN) stock, but cautious about paying the going market price of 15.12/share, might benefit from considering selling puts among the...
Stock Options Channel·1y ago
News Placeholder
Alps Advisors Inc. Boosts Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Alps Advisors Inc. raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent filing...
Zolmax·2y ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down to $16.68
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $16.68, but opened at $16.34. Day One...
Zolmax·2y ago

Latest DAWN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.